Company*
(Country; Symbol)

University/
Non-Profit@

Type Of
Agreement

Product Area

Details (Date)


Acacia Research Corp. (ACRI)
and its subsidiary, Combimatrix
KK

Research Center for Advanced Science and Technology at the University of Tokyo (Japan)

Technology access collaboration and purchasing agreement

To install a Combimatrix gene chip synthesizer

The parties also entered a multi-year deal to purchase blank chips to aid in development of diagnostic microarray applications, drug lead development and target gene identification (5/30)

Advanced
Biosystems Inc.
(subsidiary of
Analex Corp.; ANLX)

Defense Advanced Research Projects Agency

Eight-month contract

To initiate studies to develop immune system research models

Contract is worth $3M (8/1)

Advanced Biotherapy
Inc.
(OTC
BB:ADVB)

Department of Energy's Pacific Northwest National Laboratory

Cooperative research and development agreement

For a project titled "Anti-Cytokine Antibodies for Treating Immune- Mediated Diseases"

The agreement is for the development of high-affinity humanized antibodies to gamma interferon (6/3)

Ambion Inc.*

Harvard Medical School

Worldwide nonexclusive licensing agreement

For a patent application covering a mammalian small interfering RNA expression vector

Financial terms were not disclosed (7/23)

American Biogenetic Sciences Inc.
(MABA)

Russian Federation Mexico, the countries of Central and South America and the People's Republic of China

Exclusive distribution agreement

To distribute an oral smallpox vaccine in the U.S., Canada,

The company is seeking partners to test, market and distribute the vaccine (6/6)

Amersham Biosciences
(unit of Amersham
plc; UK; NYSE:
AHM)

Sloan-Kettering Institute

Two-year collaboration

For the Functional Proteomics Project

The project was established to develop the first technology to scan the entire expressed human genome in a day to test each gene for its function in a cellular process (7/29)

Atlantic Technology Ventures Inc. (OTC BB:
ATLC)

The inventors of ATV-02

Licensing agreement

ATV-02, an antimicrobial agent for the local treatment of topical infections

Terms of the deal were not disclosed (7/9)

AxCell
Biosciences
(subsidiary of
Cytogen Corp.; CYTO)

National Cancer Institute

Cooperative research and development agreement

To research TEY1, a newly discovered metastasis suppressor gene for prostate
cancer

The NCI will provide biological and biochemical information on the TEY1 gene and its protein, while AxCell will provide SH3 domain interaction data from its ProChart database to identify the protein or proteins that inter- act with the TEY1 protein (6/18)

AxCell
Biosciences
(subsidiary of
Cytogen Corp.; CYTO)

National Cancer Institute

Cooperative research and development agreement

To apply AxCell's
protein interaction mapping technology for researching tyrosine kinases and serine-threonine kinases, and how they impact signaling pathways within cells

AxCell will have an exclusive option for a commercialization license to all inventions, such as drug candidates and new methods of screening (7/17)

Beyond Genomics
Inc.*

Boston University School of Medicine

Strategic research alliance

To establish
collaborative research programs in multiple clinical areas, such as cardiovascular disease, oncology and central nervous system disorders

BUSM will provide access to its research faculty and clinical experts, while Beyond Genomics will provide access to its systems biology technologies and drug discovery research capabilities (5/23)

Biokeys
Pharmaceuticals
Inc.
(Pink Sheets: BKYS)

National Institutes
of Health

Exclusive worldwide sublicensing agreement

For U.S. Patent No. 5,562,905, which complements patents
and technology licensed by Biokeys from The University of Texas M.D. Anderson Cancer Center

Biokeys will use the patents and technology to develop BlockAide/CR, an HIV viral entry inhibitor (7/8)

Bioplex Corp.*

Indiana University

Licensing agreement

Technology for the synthesis of optically encoded microbeads and nanobeads for human health applications

The technology will be used for drug discovery and clinical diagnostics (5/21)

ComGenex
Inc.*
(Hungary)

New York Blood Center

Extended collaboration

For an ADME/Tox optimization, synthesis and screening effort for generating therapeutic agents suitable for HIV treatment

ComGenex will be responsible for ADME/Tox and medicinal lead optimization, as well as chemistry; the center will per- form screening activities; any commercial results of the collaboration will be shared (6/27)

Diversa Corp.
(DVSA)

Marine Bioproducts Engineering Center at the University of Hawaii at Manoa

Biodiversity access and research collaboration agreement

For the right to discover genes from existing material collections and from environmental samples

Samples will be collected by the university in and around Hawaii with the intent of commercializing resulting products; financial terms were not disclosed (6/4)

Dyax Corp.
(DYAX)

University
of Arizona

Exclusive rights agreement

To a cancer target, an integrin cell surface receptor found in precancerous prostate lesions and in invasive prostate cancer, but not in normal prostate cells

Dyax will use its phage display technology to identify human antibodies and peptides that specifically bind to the target (7/11)

Elixir Pharma-
ceuticals
Inc.*

Massachusetts Institute of Technology

Licensing agreement

To patents and patent applications that relate to founding scientist Lenny Guarente's discoveries

The discoveries are associated with longevity and the SIR-2 (silent information regulation) gene (6/3)

EpiTan Ltd.
(Australia;
ASX:EPT)

Southern Research Institute

Collaborative agreement

To develop a sustained-delivery formulation of Melanotan for use in EpiTan's clinical trial program

Financial terms were not disclosed (6/6)

Exegenics Inc.
(EXEG)

University of California and the University of British Columbia (Canada)

Commer-
cialization agreement

To use enzyme targets that can serve in the development of drugs to fight tuberculosis

Research on the enzymes demonstrated a direct correlation between depletion of mycothiol and a susceptibility to antibiotics (6/28)

Exhale
Therapeutics
Inc.*

Brigham and Women's Hospital

Licensing agreement

For intellectual property related to the use of hyaluronic acid to prevent group A streptococcal pharyngitis

Financial terms were not disclosed (7/30)

FeRx Inc.*

National Cancer Center Research Institute (Japan)

Research collaboration

To develop a tumor- targeting gene transfer approach using FeRx's magnetic targeted carrier drug delivery technology

A variety of genetic vectors, including plasmid DNA, adenoviruses and antisense oligonucleotides, will be studied and combined with the FeRx MTC technology (6/24)

Genetix Group
plc
(UK; LSE:
GTX)

Medical Research Council's Human Genome Mapping Project Resource Center (UK)

Collaboration

To develop equipment and systems to quicken the process of identifying the role of proteins in human health and disease

The collaboration is worth 2.5M (US$3.9M), funded by the British Department of Trade and Industry as well as both participants; it is aimed at generating maps to reveal different protein interactions (7/22)

Genteon Inc.*

Institute for Genetic Medicine at the Keck School of Medicine of the University of Southern California

Research collaboration

To develop methods for studying cancer genetics

The university team will use Genteon's Capella 400 Genetic Analysis System to study genetic mutations and the regulation of gene expression associated with certain cancers (7/18)

Hydro Med Sciences Inc.*

Institute of Macromolecular Chemistry of the Academy of Sciences of the Czech Republic

Agreement

To provide Hydro Med the option to acquire worldwide development and commercialization rights to a polymer system

The institute will complete certain preclinical studies for Hydro; financial terms were not disclosed (6/10)

Illumina Inc.
(ILMN)

University of North Carolina Pulmonary and Cystic Fibrosis Research Center

Commercial agreement

To provide single nucleotide polymorph- ism genotyping services on a sample collection provided by the center

Illumina will design functional assays for many of the SNP loci provided by the center, then use its BeadArray technology to genotype specified SNPs in the sample set (5/31)

Illumina Inc.
(ILMN)

Wellcome Trust Sanger Institute (UK)

Agreement

To provide single nucleotide polymorph- ism genotyping services on a SNP collection provided by the Wellcome Trust

Illumina will develop assays for the SNP collection and use its BeadArray technology to genotype SNPs (7/24)

Invitrogen
Corp.
(IVGN)

Columbia
University

Licensing agreement

For specific Chinese hamster ovary cell lines useful in drug discovery research and in the bioproduction of therapeutic proteins

The license covers the sale of dhfr-negative CHO cells for research use only, but not the media used to maintain and grow those cells (5/22)

IP Genesis
Inc.*

Baylor College of Medicine

Nonexclusive licensing agreement

For IP's Comparative Sequence Assembly technology

The technology helps decipher the function of the human genome by determining sequences that are conserved across species and stand out among the majority of highly variable junk DNA (7/8)

Large Scale
Biology Corp.
(LSBC)

Institute of
Infectious Disease and Molecular Medicine at the University of Cape Town (South Africa)

Collaboration

For the development and manufacture of vaccines intended to protect against infectious diseases

The vaccines will be developed for HIV and human papillomavirus, among others (7/9)

Large Scale
Biology Corp.
(LSBC)

National Institute
of Environmental Health Sciences

Five-year contract agreement

For work performed at Large Scale's proteomics facility for the National Center for Toxicogenomics

Large Scale will use its ProGEx protein expression analysis technology in the effort, and is expected to analyze a number of samples each year (7/24)

Large Scale
Biology Corp.
(LSBC)

National University
of Singapore

Collaborative research agreement

For Large Scale's Plurigen CM stem and progenitor cell cultivation product

Initial studies will focus on enhancing proliferation of human peripheral blood stem cells, umbilical cord blood stem cells and mesenchymal stem cells in vitro with the aid of Plurigen (6/14)

Lorus
Therapeutics
Inc.
(Canada; OTC BB: LORFF)

National Cancer Institute

Supply agreement

For Lorus' lead anti- sense drug, GTI-2040, for multiple clinical trials to evaluate its efficacy in a range of cancers

Lorus and the NCI will select cancer indications and suitable development programs for trials the NCI will sponsor with GTI- 2040 alone or in combination with other therapies; Lorus will manufacture and provide drug for all trials (6/18)

Lynx
Therapeutics

Inc.
(LYNX)

Institute for
Systems Biology

Collaboration

To study prostate cancer gene expression

The agreement features the application of Lynx's Massively Parallel Signature Sequencing technology to uncover differentially expressed genes in prostate cancer; financial details were not disclosed (5/21)

Lynx
Therapeutics

Inc.
(LYNX)

Ludwig Institute for Cancer Research

Service agreement

To study cancer gene expression

Lynx will receive payments for genomics discovery services it will perform on cancer samples provided by the institute (7/18)

MacroGenics
Inc.*

University of Texas Southwestern Medical Center

Agreement

To establish a MacroGenics research site in Dallas for infectious disease target identification and development of new methods for genetic immunization

MacroGenics is licensing a patent portfolio from the medical center related to new vaccine antigens, adjuvants and methods of immunization (6/6)

MerLion Pharmaceuticals
Pte. Ltd.*
(Singapore)

Johns Hopkins Singapore Pte. Ltd. (Singapore)

Research and development agreement

Related to Epstein-Barr virus-related cancers

Parties will develop a high- throughput assay based on Johns Hopkins research in viral DNA binding proteins; they will share in development and commercialization (7/25)

MerLion Pharmaceuticals
Pte. Ltd.*
(Singapore)

National Cancer Center Research Institute (Japan)

Agreement

To screen for compounds that can activate a new tumor-suppressing protein

The NCC will further characterize resulting compounds; all three parties, including Biotech Research Ventures Pte. Ltd., will share an undisclosed portion of benefits from resulting drugs discovered under the collaboration (7/8)

Mindset Bio-
pharmaceuticals
Inc.*
(Israel)

New York University School
of Medicine

Agreement

To license a vaccine technology for the treatment of Alzheimer's disease

Mindset becomes the worldwide exclusive licensee of the vaccine technology, Amyrex (7/22)

Molecular
Mining
Corp.*

University of California at San Francisco

Collaboration

To investigate the effects of interferon beta therapy on multiple sclerosis patients

Researchers are investigating the effect of interferon beta-1b in MS patients and healthy individuals (6/5)

Nanogen Inc.
(NGEN)

Centers for Disease Control and Prevention

Development site agreement

To install a NanoChip molecular biology workstation at the CDC's foodborne and diarrheal diseases branch in Atlanta

Nanogen will receive certain licensing and commercialization rights to the assays developed by the CDC (6/6)

Nanogen Inc.
(NGEN)

NASA's Ames Research Center

Collaboration

To provide a Nano- Chip Molecular Biology Workstation to NASA in exchange for commercialization rights to NASA- developed intellectual property and assays

NASA will use the Nanogen platform to develop and validate protocols for specific single nucleotide polymorphism and short tandem repeat analyses related to mission requirements (6/12)

NeoGenesis
Pharmaceuticals
Inc.*

Massachusetts General Hospital

Development agreement

To discover and develop drugs that target cancer and inflammatory diseases

Financial terms were not disclosed (7/23)

Oxford
GlycoSciences

plc
(UK; OGSI; LSE:OGS)

Cystic Fibrosis Foundation Therapeutics Inc. (a nonprofit affiliate of the Cystic Fibrosis Foundation)

Research collaboration

To discover and validate serum biomarkers of cystic fibrosis and associated pulmonary complications

OGS will apply its industrial- scale proteomics technology to analyze clinical samples collected by the University of North Carolina at Chapel Hill to identify serum proteins that predict early CF lung disease; the foundation will pay up to US$5.5M, including an up-front technology access fee (7/12)

Panacea Pharm-
aceuticals
Inc.*

Rhode Island Hospital and Brown University

Collaborative research agreement

For the development of drugs to prevent and treat oxidative stress- induced neurodegeneration in a number of conditions

The agreement provides an option that would grant an exclusive worldwide license to Panacea for discoveries made through the collaboration (6/27)

Proneuron Biotechnologies
Inc.*
(Israel)

Craig Hospital

Collaboration

To continue the development of Proneuron's macrophage cell therapy for treatment of spinal cord injuries

The collaboration includes the establishment of the first Pro- neuron Cell Center in the U.S. (6/24)

Regma Bio
Technologies
Ltd.
(UK; OTC
BB:RBTL)

Institut Pasteur (France)

Research agreement

To develop phage therapies in response to antibiotic resistance, particularly against Mycobacterium tuberculosis

Financial terms were not disclosed (6/17)

Replicon Technologies
Inc.*

University of Alabama at Birmingham Research Foundation

License agreement

For rights to the use of replicon technology in the development of vaccines against infectious diseases and therapeutic vaccines against human cancers

Replicon gains exclusive rights to the commercial use of licensed patents for replicons in the field of human vaccines (6/11)

Seaphire International
Inc.*

University of Toronto Innovations Foundation (Canada)

License agreement

For exclusive worldwide rights to technology used to create salt-tolerant plants

Research using the technology has developed tomato and canola plants that grow and pro- duce fruit and seeds when irrigated with water that is 33% the salinity level of saltwater (7/17)

Syngenta AG* (Switzerland)

National Institute of Agrobiological Sciences (Japan)

Agreement

To share the Syngenta rice genome draft sequence data with the International Rice Genome Sequencing Project

The Syngenta contribution is expected to accelerate completion of a finished sequence and reduce overall project costs (5/23)

Telik Inc.
(TELK)

Arizona Cancer Center

Licensing agreement

To obtain exclusive worldwide rights to intellectual property, including small-molecule drug candidates for four cancer targets

Telik is applying its TRAP drug discovery technology to identify compounds active against cancer targets identified by the Arizona researchers (7/17)

Variagenics
Inc.
(VGNX)

St. Jude Children's Research Hospital

License agreement

For exclusive rights in the field of oncology to develop diagnostic tests predictive of drug response

The agreement covers a patent application claiming CYP3A5 genotyping methods and diagnostic test kits predictive of variable expression of CYP3A5 (7/26)

Vical Inc.
(VICL)

Dale and Betty Bumpers Vaccine Research Center and the National Institute of Allergy and Infectious Diseases

Contract

To manufacture clinical-grade supplies of an experimental DNA vaccine against Ebola for initial clinical development

Further details were not disclosed (7/17)

Viragen Inc.
(AMEX:VRA)

University of
Miami's Office
of Technology Transfer

Development agreement

For anticancer technology

The project is designed to develop a form of an immune-enhancing drug that has shown promise by inhibiting tumor growth in cancers; Viragen also receives an option to acquire an exclusive worldwide license in order to commercialize the technology (7/30)

Xcyte
Therapies

Inc.*

University of Pennsylvania

Licensing agreement

To a genetically modified cell line that could be used to activate and grow T cells

The Xcellerate Technology employs proprietary beads that deliver signals required to activate a patient's T cells, which can be used to treat a range of diseases (5/22)

Xechem International
Inc.
(OTC
BB:ZKEM)

National Institute
for Pharmaceutical Research and Development (Nigeria)

Licensing agreement

For exclusive worldwide rights to a drug product for treating and managing sickle-cell anemia

The product is in Phase III trials in Nigeria (8/1)

Zyomyx Inc.*

Partners
HealthCare

Strategic alliance

To apply Zyomyx's protein profiling biochip system to clinical research

Zyomyx and Partners will establish a core protein profiling research facility to focus primarily on the identification and validation of protein biomarkers to improve the understanding and diagnosis of complex diseases (6/24)


Notes:

This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board

No Comments